PHR1851
Olmesartan Medoxomil
Pharmaceutical Secondary Standard; Certified Reference Material
Synonym(s):
Olmesartan medoxomil
About This Item
Recommended Products
grade
certified reference material
pharmaceutical secondary standard
Quality Level
agency
traceable to BP 1173
traceable to Ph. Eur. Y0001405
traceable to USP 1478367
API family
olmesartan
CofA
current certificate can be downloaded
packaging
pkg of 200 mg
application(s)
pharmaceutical
format
neat
storage temp.
-10 to -25°C
SMILES string
CCCC1=NC(C(O)(C)C)=C(C(OCC2=C(C)OC(O2)=O)=O)N1CC(C=C3)=CC=C3C4=CC=CC=C4C5=NN=NN5
InChI
1S/C29H30N6O6/c1-5-8-23-30-25(29(3,4)38)24(27(36)39-16-22-17(2)40-28(37)41-22)35(23)15-18-11-13-19(14-12-18)20-9-6-7-10-21(20)26-31-33-34-32-26/h6-7,9-14,38H,5,8,15-16H2,1-4H3,(H,31,32,33,34)
InChI key
UQGKUQLKSCSZGY-UHFFFAOYSA-N
Gene Information
human ... AGTR1(185)
Looking for similar products? Visit Product Comparison Guide
General description
Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Olmesartan Medoxomil is an AT1 subtype angiotensin-II receptor antagonist used in the management of hypertension. It prevents angiotensin II from binding to the AT1 receptors, thereby decreasing vasoconstriction.
Application
- Development and validation of an isocratic ultra-high performance liquid chromatography (UHPLC) based stability indicating method to determine olmesartan medoxomil and amlodipine besylate in combined tablet dosage forms
- Simultaneous determination of Olmesartan medoxomil and chlorthalidone by reversed phase-high performance liquid chromatography (RP-HPLC) in tablets
- Quantification of olmesartan medoxomil and its degradation products in bulk drugs and pharmaceutical formulations by using a systematic quality by design (QbD)-based reverse-phase liquid chromatography method
- Reversed phase-high performance liquid chromatographic (RP-HPLC) analysis of olmesartan medoxomil and hydrochlorothiazide in their combined tablet dosage form
- Determination of olmesartan medoxomil and amlodipine besylate in their combined tablet dosage form by absorption subtraction method, ratio subtraction with extended ratio subtraction method, dual wavelength technique, and second order derivative spectrophotometry
Analysis Note
Footnote
related product
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Don't see the Right Version?
If you require a particular version, you can look up a specific certificate by the Lot or Batch number.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service